SCHEMBL490810

SCHEMBL490810

CCOC(=O)C1Cc2ccccc2C1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.70
KDM4E B2RXH2 3/20 0.70
MEN1 O00255 3/20 0.70
KMT2A Q03164 3/20 0.70
ALDH1A1 P00352 3/20 0.70
GAA P10253 1/20 0.70
HPGD P15428 1/20 0.70
HSD17B10 Q99714 1/20 0.70
MAPK1 P28482 1/20 0.51
ATM Q13315 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.48
ACHE P22303 2/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.45
METAP1 P53582 2/20 0.44
CYP1A2 P05177 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 1/20 0.42
PTGS2 P35354 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31460799 1.00 MAPT (0.70) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL947365 0.85 ALDH1A1 (0.55) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL2919195 0.85 MAPT (0.51) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL29683518 0.85 ALDH1A1 (0.55) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL5346346 0.84 MAPT (0.50) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL19417331 0.84 MAPT (0.52) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL7714519 0.83 ALDH1A1 (0.52) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL1000380 0.83 ACHE (0.51) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL29476747 0.83 ACHE (0.51) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL7950190 0.83 MEN1 (0.58) MAPTKDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-11246483-A None JP disclosed
CN-113004109-A Asymmetric synthesis method of chiral alpha-hydroxy-beta-ketonic acid ester compound 浙江工业大学 2021-06-22 CN disclosed
US-9975848-B2 Inhibitors of HIV-1 entry and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-05-22 US disclosed
US-9975848-B2 Inhibitors of HIV-1 entry and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-05-22 US disclosed
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF BRYN MAWR COLLEGE 2017-08-17 US disclosed
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF BRYN MAWR COLLEGE 2017-08-17 US disclosed
US-9701684-B2 Chiral fluorinating reagents OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2017-07-11 US disclosed
US-9376387-B2 Oxidisable pyridine derivatives, their preparation and use as anti-alzheimer agents INSA INST NAT DES SCIENCES APPLIQUEES DE ROUEN (FR) 2016-06-28 US disclosed
WO-2016025681-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-02-18 WO disclosed
US-20150353493-A1 OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (FR) 2015-12-10 US disclosed
US-7307193-B2 Catalyst containing a Group VIII metal encapsulated in a polymer that has side chains containing an aromatic substituent; stable even in air, easy to recover, and reusable JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) 2007-12-11 US disclosed
US-7307193-B2 Catalyst containing a Group VIII metal encapsulated in a polymer that has side chains containing an aromatic substituent; stable even in air, easy to recover, and reusable JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) 2007-12-11 US disclosed
EP-1047674-B1 PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVES EISAI CO LTD (JP) 2005-03-30 EP disclosed
EP-0991772-A1 METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL VICINAL AMINOALCOHOLS Biocatalytics, Inc. (US) 2000-04-12 EP disclosed
JP-H11246483-A PRODUCTION OF ADDITION PRODUCT TEIKOKU CHEM IND CORP LTD 1999-09-14 JP disclosed
US-5942644-A Precursors for the production of chiral vicinal aminoalcohols BIOCATALYTICS, INC. (US) 1999-08-24 US disclosed
EP-0738712-B1 Anti-arrhythmic and cardioprotective substituted indenoylguanidines HOECHST AG (DE) 1999-08-18 EP disclosed
WO-1998054350-A1 METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL VICINAL AMINOALCOHOLS BIOCATALYTICS, INC. (US) 1998-12-03 WO disclosed
US-5733934-A Antiarrythmic and cardioprotective substituted indenoylguanidines HOECHST AKTIENGESELLSCHAFT (DE) 1998-03-31 US disclosed
EP-0738712-A1 Anti-arrhythmic and cardioprotective substituted indenoylguanidines HOECHST AKTIENGESELLSCHAFT (DE) 1996-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353493-A1 OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS CBR3, CBR1, CYB5R3 MAPT 454/4885KDM4E 2033/4885MEN1 4086/4885
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF CD4, CD81, ICAM1 MAPT 2115/4885KDM4E 2784/4885MEN1 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.